New CRISPR technology can selectively target and destroy cancer cells, including ‘undruggable’ types, promising advances in consumer safety and treatment.
Browsing Category
Healthcare operations
26 posts
Fangzhou Launches Novo Nordisk’s Once-Weekly Basal Insulin/GLP-1 Therapy In China
Fangzhou has launched Novo Nordisk’s once-weekly basal insulin and GLP-1 therapy in China, marking a significant step in diabetes treatment availability.
How To Make The Most Of Daily Postpartum Check-ins At Home
Guidance on how first-time mothers can effectively utilize daily postpartum check-ins during the first two weeks after discharge to improve recovery and safety.
4DMT Announces Positive 2-Year Data From PRISM Phase 2B Clinical Trial In A Broad Wet AMD Population
4DMT announces favorable 2-year data from its PRISM Phase 2b trial targeting wet AMD, showing promising efficacy and safety outcomes.
Lynk Pharmaceuticals Announces Completion Of Patient Enrollment In Phase III Clinical Trial Of Zemprocitinib For Ankylosing Spondylitis
Lynk Pharmaceuticals has finished enrolling patients in its Phase III clinical trial for Zemprocitinib targeting ankylosing spondylitis, marking a key milestone.
Women’s Health Radar
A new digital tool aims to identify perimenopausal symptoms early in women aged 40-58, enabling timely care and reducing health and work disruptions.
Retirement Care Planner
A new retirement care planning tool is being tested to help adult children coordinate care and finances for aging parents amid rising costs and complexity.
Voluntary Recall Of Two Lots Of PEDIGREE® Can High Protein Chopped Chicken & Duck Flavor Wet Dog Food Due To Potential Fraudulent Distribution Of Product Which May Contain Foreign Material
Pedigree® has voluntarily recalled two lots of its Can High Protein Chopped Chicken & Duck Flavor due to potential foreign material contamination.
Xeris Biopharma Surges In Global Coverage
Xeris Biopharma is experiencing a surge in worldwide media coverage, with 23 mentions this week, indicating increased interest in the company and its developments.
Partner Therapeutics Announces Publication of Results From the eNRGy Trial of Zenocutuzumab in Patients with NRG1+ Cholangiocarcinoma in Journal of Clinical Oncology (JCO)
Partner Therapeutics announced the publication of the eNRGy trial results of Zenocutuzumab in NRG1+ cholangiocarcinoma, detailed in the Journal of Clinical Oncology.
